PL3725803T3 - Cząsteczki wiążące, które wiążą ludzki czynnik C2 dopełniacza i ich zastosowania - Google Patents

Cząsteczki wiążące, które wiążą ludzki czynnik C2 dopełniacza i ich zastosowania

Info

Publication number
PL3725803T3
PL3725803T3 PL20165165T PL20165165T PL3725803T3 PL 3725803 T3 PL3725803 T3 PL 3725803T3 PL 20165165 T PL20165165 T PL 20165165T PL 20165165 T PL20165165 T PL 20165165T PL 3725803 T3 PL3725803 T3 PL 3725803T3
Authority
PL
Poland
Prior art keywords
binding molecules
complement factor
human complement
bind human
bind
Prior art date
Application number
PL20165165T
Other languages
English (en)
Polish (pl)
Inventor
Cornelis Erik Hack
Cafer YILDIZ
Louis Boon
Petrus Johannes Simons
Original Assignee
Broteio Pharma B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Broteio Pharma B.V. filed Critical Broteio Pharma B.V.
Publication of PL3725803T3 publication Critical patent/PL3725803T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL20165165T 2013-05-23 2014-05-22 Cząsteczki wiążące, które wiążą ludzki czynnik C2 dopełniacza i ich zastosowania PL3725803T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP13168941 2013-05-23
EP14729463.1A EP2999714B1 (en) 2013-05-23 2014-05-22 Binding molecules that bind human complement factor c2 and uses thereof
PCT/NL2014/050327 WO2014189378A1 (en) 2013-05-23 2014-05-22 Binding molecules that bind human complement factor c2 and uses thereof
EP20165165.0A EP3725803B1 (en) 2013-05-23 2014-05-22 Binding molecules that bind human complement factor c2b and uses thereof

Publications (1)

Publication Number Publication Date
PL3725803T3 true PL3725803T3 (pl) 2022-04-04

Family

ID=48485015

Family Applications (2)

Application Number Title Priority Date Filing Date
PL20165165T PL3725803T3 (pl) 2013-05-23 2014-05-22 Cząsteczki wiążące, które wiążą ludzki czynnik C2 dopełniacza i ich zastosowania
PL14729463T PL2999714T3 (pl) 2013-05-23 2014-05-22 Cząsteczki wiążące, które wiążą ludzki czynnik c2 dopełniacza oraz ich zastosowania

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL14729463T PL2999714T3 (pl) 2013-05-23 2014-05-22 Cząsteczki wiążące, które wiążą ludzki czynnik c2 dopełniacza oraz ich zastosowania

Country Status (14)

Country Link
US (2) US9944717B2 (enExample)
EP (2) EP3725803B1 (enExample)
JP (3) JP2016520313A (enExample)
CN (1) CN105492461B (enExample)
AU (1) AU2014269193C1 (enExample)
CA (1) CA2913318C (enExample)
DK (2) DK3725803T3 (enExample)
ES (2) ES2904709T3 (enExample)
HU (2) HUE049769T2 (enExample)
LT (2) LT2999714T (enExample)
MX (1) MX366046B (enExample)
PL (2) PL3725803T3 (enExample)
PT (2) PT3725803T (enExample)
WO (1) WO2014189378A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS63212B1 (sr) 2012-11-02 2022-06-30 Bioverativ Usa Inc Antikomplementna c1s antitela i njihove primene
DK3725803T3 (da) * 2013-05-23 2022-03-07 Broteio Pharma B V Bindingsmolekyler som binder human komplementfaktor C2b, og anvendelser deraf
EP3525583B8 (en) 2016-10-12 2025-09-10 Bioverativ USA Inc. Anti-c1s antibodies and methods of use thereof
FI3893924T3 (fi) * 2018-12-13 2024-10-04 argenx BV Ihmisen komplementtitekijän C2B vasta-aineita sekä niiden käyttötapoja
GB2584105B (en) 2019-05-21 2023-08-02 Argenx Bvba Methods of treating neuropathy
US20220332804A1 (en) * 2019-08-12 2022-10-20 Csl Innovation Pty Ltd. Complement C2 Binding Proteins and Uses Thereof
EP4469475A1 (en) * 2022-01-29 2024-12-04 Kira Pharmaceuticals (Suzhou) Ltd. Anti-c2 antibodies and uses thereof
GB202407051D0 (en) 2024-05-17 2024-07-03 argenx BV Methods of treating osteoarthritis pain

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
ATE435873T1 (de) 2000-03-23 2009-07-15 Genentech Inc Anti-c2/c2a inhibitoren zur komplement aktivierung
DK3725803T3 (da) 2013-05-23 2022-03-07 Broteio Pharma B V Bindingsmolekyler som binder human komplementfaktor C2b, og anvendelser deraf

Also Published As

Publication number Publication date
AU2014269193B2 (en) 2019-08-15
DK2999714T3 (da) 2020-06-02
CN105492461B (zh) 2019-11-26
EP2999714B1 (en) 2020-04-01
HUE057858T2 (hu) 2022-06-28
MX2015016120A (es) 2016-10-28
AU2014269193C1 (en) 2020-02-20
MX366046B (es) 2019-06-26
DK3725803T3 (da) 2022-03-07
JP2023002684A (ja) 2023-01-10
PT2999714T (pt) 2020-04-30
CA2913318C (en) 2024-03-26
US10717785B2 (en) 2020-07-21
US20160108134A1 (en) 2016-04-21
US20180319895A1 (en) 2018-11-08
JP7163254B2 (ja) 2022-10-31
EP3725803B1 (en) 2021-12-15
JP2020007318A (ja) 2020-01-16
US9944717B2 (en) 2018-04-17
EP2999714A1 (en) 2016-03-30
ES2904709T3 (es) 2022-04-05
LT3725803T (lt) 2022-03-10
WO2014189378A1 (en) 2014-11-27
PL2999714T3 (pl) 2020-10-19
JP7414929B2 (ja) 2024-01-16
AU2014269193A1 (en) 2015-12-17
ES2784616T3 (es) 2020-09-29
JP2016520313A (ja) 2016-07-14
HUE049769T2 (hu) 2020-10-28
PT3725803T (pt) 2021-12-24
CN105492461A (zh) 2016-04-13
LT2999714T (lt) 2020-07-10
EP3725803A1 (en) 2020-10-21
CA2913318A1 (en) 2014-11-27
HK1223385A1 (zh) 2017-07-28

Similar Documents

Publication Publication Date Title
IL276106A (en) Garp-binding proteins and their uses
ZA201505209B (en) Binding molecules for bcma and cd3
IL254223A (en) CD20 binding compounds and their uses
IL240045A0 (en) Antigen-binding molecules activate bi-specific t cells
SG11201505762XA (en) Il-11r binding proteins and uses thereof
ZA201803841B (en) Binding molecules specific for asct2 and uses thereof
ES3048528T3 (en) Ligand binding molecules and uses thereof
PT3725803T (pt) Moléculas de ligação que se ligam ao fator c2b do complemento humano e suas utilizações
GB201306588D0 (en) Peptides and Binding Partners Therefor
ZA201503962B (en) Fines binding process and binding composition thereof
HU4488U (en) Plaster-coated and edge-protected chipboard